Palliative radiotherapy is effective in the treatment of bone metastases but is under-utilized, possibly because it is perceived to be expensive. We performed a cost-utility analysis of palliative radiotherapy for bone metastases, evaluating both the actual cost of radiotherapy as well as its impact on quality of life by adjusting for the variation in response to treatment. Hospital records between July 1991 and July 1996 were reviewed to ascertain the number of patients treated with palliative radiotherapy for bone metastases, the average number of fields of radiation delivered to each patient and the average duration of survival. Partial and complete response rates to palliative radiotherapy were obtained from a review of all published randomized controlled trials of radiation treatment of bone metastases. Utility values were assigned to the response rates, and an overall adjusted response rate to radiotherapy was derived. The cost of delivering a field of radiation was calculated. The total cost was divided by the total number of response months to give a utility-adjusted cost per month of palliative radiotherapy. The utility-adjusted cost per month of palliative radiotherapy of bone metastases was found to be AUS$ 100 per month or AUS$ 1200 per utility-adjusted life-year. This study demonstrates that, contrary to popular perception, palliative radiotherapy is a cost-effective treatment modality for bone metastases.
INTRODUCTION
Cancer pain is widespread and constitutes an important but neglected public health problem in many developed countries.
It has been estimated that 45-100% of patients with advanced cancer experience moderate to severe pain, and 20-40% of these patients are inadequately treated for the pain. 'Every day more than three and a half million people suffer from cancer pain, but only a fraction receive treatment for it.' 1 Metastasis to bone is common in advanced cancer and frequently results in pain and impaired quality of life. Radiotherapy is known to be effective in reducing pain, preventing fractures and increasing mobility in patients with skeletal metastases.
Several studies have demonstrated its effectiveness in the treatment of bone metastases. [2] [3] [4] [5] [6] [7] [8] [9] Ninety percent of patients with symptomatic bone metastases experience some degree of pain relief with palliative radiotherapy. 10 The Swedish Council on
Technology Assessment in Health Care concluded that palliative radiotherapy is both clinically effective and economically justified and is therefore 'the treatment method of choice in patients who have pain localized to a skeletal region with a verified metastatic tumour.' 11 A review of current Swedish practice patterns in oncology showed that only one in 10 cancer patients received palliative radiotherapy for bone metastases, which constitutes a significant under-utilization of radiotherapy. 11 Under-utilization of palliative radiotherapy for bone metastases, despite its known effectiveness, could perhaps be due to the fact that both palliative treatment and radiotherapy are perceived to be expensive.
Radiotherapy is widely perceived to be an expensive treatment modality, possibly because it is highly dependent on technology and because the initial cost of equipment is high.
However, recent global cost analyses have shown that, in fact, radiotherapy is extremely cost-effective. Glazebrook 12 showed that the cost of radiotherapy in Canada was C$ 661 per 
METHODS

Patients
All patients treated by radiation with palliative intent for bone metastases between July 1991 and July 1996 were identified from the database and tumour registry maintained in the department of radiation oncology at Westmead Hospital. This database records the diagnosis, treatment details and patient status of all patients undergoing treatment in the hospital. An ongoing program of follow up constantly updates patient status.
Yearly letters were sent to general practitioners and referring doctors when follow up was not performed in the department.
The New South Wales Cancer Registry was also reviewed when the outcome was not known. Survival data were supplemented by checking whether the New South Wales Births, Deaths and Marriages register had recorded the death of the patient.
Patients were eligible for the study if they received palliative radiotherapy for a bone metastasis. There were no restrictions on patient age, sex or tumour type.
A survival curve for the entire group of patients was calculated using the method of Kaplan-Meier. 14 The area under the survival curve gave an estimate of the average survival of patients treated by radiotherapy. This area was obtained numerically using a standard method (Simpson's rule). 15 The bootstrap technique was used to determine the appropriate limits to construct 95% confidence intervals around the estimate of the area under the curve. 16 The average number of fields of radiation delivered to this group of patients was determined.
Response
It is difficult to measure or compare any outcomes of the palliative treatment of bone metastases with radiotherapy because of the large variation in response rates to treatment that can occur. Most patients experience some amount of pain relief after radiotherapy for bone metastases. However, the degree of response (i.e. degree of pain relief) to radiotherapy can vary from a complete response (total pain relief) to a partial response (partial relief of pain) to no response (no pain relief).
The definition of partial response is especially problematic as there is no consensus in the literature. 17 It therefore becomes necessary to adjust for differences in response rate when measuring the outcomes and calculating the costs of palliative radiation of bone metastases.
A literature review of all published randomized controlled studies of radiation treatment of bone metastases was conducted. Only studies that specified both complete and partial response rates were included in the analysis. [2] [3] [4] [5] [6] [7] [8] [9] Response rates (partial and complete response rates) to palliative radiotherapy were compiled from the studies.
Utility
It was assumed that a partial response, or partial reduction, in pain following radiotherapy would have some value to the patient, albeit less than the value of a complete response (CR).
The effect of a CR rate was weighted at 1 and that of a partial response rate (PR) at 0.5. An overall adjusted response rate was derived by totalling the weighted values of the complete and the partial response rates.
Sensitivity analysis
The assumption that a PR has a utility value that is worth half of a CR was tested by varying the PR rates (from 0.0 to 0.9). The overall response rate and cost were then calculated for each value.
Sensitivity analysis was also conducted on the assumption that the duration of response to palliative radiation is equivalent to the patient's duration of survival. This assumption was tested by reducing the duration of response to be equivalent to half of the patient's recorded duration of survival, and then calculating the corresponding number of life months of response and the cost of radiotherapy per utility-adjusted month.
Costs
The cost of delivering a field of radiation treatment at the depart- All costs were converted to 1996 Australian dollars using the relevant Consumer Price Index information from the Australian Bureau of Statistics.
The average survival was adjusted by the response rate to
give an average duration of response. This was then multiplied by the total number of patients to give the total number of months of response. The cost was divided by the total number of response months to give a cost per month adjusted by the effectiveness of treatment in terms of response.
RESULTS
Nine hundred and three patients received palliative radiotherapy for bone metastases at Westmead Hospital between July 1991 and July 1996.
Each patient received an average of 10.9 treatment fields per course of treatment. The minimum utility-adjusted cost per month was AUS$ 68 and the maximum utility-adjusted cost was AUS$ 146 per month, taking into account the maximum and minimum adjusted response rates obtained from the literature review (Table 1) . The cost to society of palliative treatment of bone metastases with radiotherapy amounts to AUS$ 1200 per utility-adjusted life-year. Adjusted response rate = complete response rate + (partial response rate × 0.5).
Sensitivity analysis
The assumption that a PR is worth half of a CR was tested by varying the weighting of the PR rates from 0.0 to 0.9. This varied the overall response rate from 42 to 73.5%, respectively, and the cost from AUS$ 139 per month to AUS$ 80 per month (Table 2) Barton et al . 17 found that the presence or absence of pain was the single most important factor affecting the quality of life of patients with bone metastases. A cost-utility analysis of radiotherapy as a treatment for bone metastases takes into account the effect of treatment on the quality of life by using a utility approach. Utilities place a value on health states by measuring the preferences for that health state in relation to perfect (or usual) health and death. 19 In this paper, we assigned a utility value of 1 to total pain relief as a result of a complete response to radiation treatment. We assigned a utility value of 0.5 to a partial response to radiotherapy leading to partial pain relief.
The 21 Rees used the concept of Notional Patient Benefit Year (NPBY) cost, which takes into account the cost, response rate and duration of benefit but has no quality of life adjustment. 22 He found that palliative radiotherapy for bone metastases (10 fractions, response rate 75%, mean response duration 4 months)
had an NPBY cost of 1200 pounds. This comparatively higher cost is due to the fact that his calculations are based on estimated assessments of costs rather than on the measurement of actual costs. In addition, the quoted mean response duration of 4 months for palliative radiotherapy is low given that the published retreatment rates for palliative radiotherapy of bone metastases from two large randomised trials is around 16%, indicating that duration of response at the treated site for patients who were not retreated is equivalent to duration of survival. 2, 4 All the available estimates of the costs of palliative radiotherapy are considerably lower than the estimated costs of other treatment modalities for control of metastatic bone pain. to be an effective but under-utilized treatment modality for bone metastases. This study demonstrates that it also costs less than any other currently available treatments for bone metastases.
